CNS Pharmaceuticals Inc. (CNSP) said Wednesday that it has priced its underwritten public offering of 5 million shares of common stock and warrants to purchase up to 2.50 million shares of common stock.
The company will sell its common stock and warrants together at a combined public offering price of $2.00 per share and warrant.
The warrants will have an exercise price of $2.20 per share, will be immediately exercisable and will expire five years from the date of issuance.
The company noted that it has granted the underwriter a 45-day option to purchase up to an additional 750,000 shares of common stock and/or 375,000 warrants to cover over-allotments, if any.
The company plans to use the net proceeds from the offering for its Phase 2 trial for Berubicin, other research and development, and for working capital. The company expects to close the offering on or about December 28.
CNSP closed Tuesday regular trading at $2.10, down $0.37 or 14.98%. The stock further dropped $0.24 or 11.43% to $1.86 in Wednesday pre-market trading.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.